Report #2844846

Received Jun 13, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: —
Recovered: Unknown
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	UNK	—	—

Symptoms (1)

Skin hyperpigmentation

Symptom narrative

Hyperpigmentation On The Face; Initial report received on 21-May-2025. This report was retrieved from a social media post. A consumer reported that a patient (gender, race, and ethnicity not reported) received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization and the developed hyperpigmentation on their face. No medical history or concomitant medications were reported. On an unknown date, the patient received an unspecified dose of hepatitis B vaccine [HEPLISAV-B (lot #, expiration date, NDC #, route, and site not available). One day following administration of the vaccine, the patient underwent a laser hair removal procedure. After the procedure, the patient developed hyperpigmentation on their face. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.